My husband, Joseph, was diagnosed
6/7/02 with a GBM. He went through a surgery to remove all visable
tumor, but developed an infection (from the surgery--had to remove
the temporal bone) which required IV therapy for a month. Then, of
course, the 30 day conformal radiation which caused so many side effects--and
worse yet---the tumor grew right through the whole process and a second
surgery was done in November. This surgery was not as successful as
the first as the DR opted (thankfully) to leave the portion growing
deep within the motor area so that he would retain some motor control--"treat the tumor or treat the person," he
always reminds us. His decision to treat the remaining tumor with a GliaSite
(a potent, liquid radiation placed in a reservoir near the tumor for
seven days) --placed in position during the second surgery--was a dubious
choice to me since radiation clearly didn't work the first time.
Afterwards, Joseph had PT and OT and finally returned home. He was to
start Temador on a Monday, but I received a phone call from a biochemist
in England on the Saturday before and thankfully decided to give his treatment
a try--it made so much sense to me as I am an RN with a holistic health
background and understand healing differently then most medical people
and this man offered a completely natural product WITH NO SIDE EFFECTS!
Joseph has been taking this product since December--his MRI's showed that
he was stable--which was a godsend in and of itself. Then in June--the
best news came--tumor shrinkage!
How it works- the serum was developed using known research on the antitumor
properties of fruits and vegetables. He extracts these molecules and
the process begins. Different formulations are provided using state-of-
the-art blood analysis and cell line cultures. My husband takes 6 tsp./day
along with 2 liters of glass-bottled water and avoidance of all meats,
corn, pickles and peppers. Otherwise, all organic foods are ingested
as well as 4 cups of fresh carrot juice daily. The serum, rather than
being cytotoxic like chemotherapy--killing cells--the serum causes the
cells to go through differentiation, materation, then natural cell death.
The process takes a little longer, but causes no side effects and WORKS!
Our NS, who I didn't tell right away, is now offering others the option!
Another NO at UCLA is starting to collect data to possibly bring this
to a clinical tial. This is a long, difficult process--especially without
the financial backing of a pharmaceutical company (this stage known as "Death Valley").
To help with costs we had a fund raiser. I am now in the process of starting
a Foundation to assist others to have the option of a treatment like
this. My husband's prognosis was maybe 3 months when he didn't respond
to radiation. That was almost 10 months ago!
Please e-mail or write me if you want more info or you just want to talk.
Try several times as I'm having difficulty with my e-mail lately: firstname.lastname@example.org
Bless You All,
Mindy Formento, RN
658 Rt. 47 North
Cape May Court House, NJ 08210
top of page
Hello, my name is Tom and I have some information that i know you will
be interested in.It is a company called MORINDA., In 1996 they brought
a product to the market they called Tahitian Noni Juice.The Medical Field
Praises Tahitian Noni Juice because represents a whole New Paradigm in
the field of Natural Healing and Health Maintenance. It is a miracle juice
in a bottle, well that is what some of the medical field is saying.Ralph
Heinicke,PhD. Anne Hirazumi PhD. Dr. Ronald Edwards wrote (Tahitian Noni
is to the 21st, century what antibiotics were to 20th century-but better-)
and the list goes on.
A simple plant from French Polynesia was introduced by a friend to two
well-known food scientists, Stephen Story and John Wadsworth in 1993.
This Plant was destined to become The Most Unique and Important Natural
Health Discovery in Decades.
Morinda is decicated to enabling everyone, everywhere to have acess to
TAHITIAN NONI JUICE,
This is a Tremendous Opportunity that will help the the Financial Health
and Wealth of Thousands, eventually millions, derives its power from the
This truly unique, benefical, and exclusive product will break through
the clutter and become the industry standard for decades to come.
Tahitian Noni Juice has been used for thousands of years by the French
Polynesian People to help a wide varitey of conditions,
CANCER, IMMUNE SYSTEM FAILURE, ARTHRITIS, DIABETES,
WEIGHT LOSS, HIGH BLOOD PRESSURE, FIBROMYALGIA, CHRONIC FATIGUE SYNDROME,
ASTHMA, STRESS, ALLERGIES, ADHA, COLDS, FLU, FEVER.
Here are two web sities that they can look at. www.tahitiannoni.com/realtreasure
and one that is Testimonials
I did a google search, and there are a lot of sites, for sales and information.
Do your research
Noni a questionable magic fruit from the South Seas
For a long time, clever traders have been making good business with products
of the noni-plant (Morinda citrifolia). Preparations from the shrub believed
to have originated from Australia are regarded in folk medicine as universal
remedies for various diseases. However, valid scientific data to support
the efficacy of noni is yet to be established. The most dominant substances
of the fruit are fatty acids and polysaccharides. The roots and the bark
top of page
With Hydrazine Sulfate
*The information of the links below, has been sent to
me, I or this site make no endorsemnets of such information. as always
research the claims yourself.*
Did you know that there is a chemical that clinical evidence suggests
may be useful in the fight against the ravages of cancer? Cancer cells
need glucose. A chemical known as HYDRAZINE SULFATE has been demonstrated
to interrupt the glucose "feeding frenzy" characteristic of
growing cancer cells. This feeding frenzy and its related metabolic disturbances
in many people with cancer can cause a terrible debilitation called CACHEXIA.
Hydrazine Sulfate Hydrazine sulfate, a simple, off-the-shelf chemical,
dramatically reverses cachexia (ka-KEK-si-a), the wasting-away process
that kills two thirds of all cancer patients. This inexpensive drug, with
little or no side effects, also has a clinically documented anti-tumor
action. It causes malignant tumors to stop growing, to reduce in size,
and, in some cases, to disappear. A growing number of cancer patients
diagnosed as terminal have experienced tumor stabilization and remission
through hydrazine sulfate therapy. About half of all patients who take
hydrazine sulfate experience weight gain, restored appetite, extended
survival time, and a significant reduction in pain and suffering. Many
patients report an increase in vigor and strength and the disappearance
of symptoms of the disease, along with feelings of well-being and optimism.
While hydrazine sulfate may not be a sure-fire cancer cure, large-scale
clinical trials suggest that it effects every type of tumor at every stage.
It can be administered either alone or in combination with cytotoxic chemotherapy
or radiation to make the cancer more vulnerable to these standard forms
Research on the effects of HYDRAZINE SULFATE administered on carefully
structured doses has shown it
to be beneficial to many cancer patients. It can be used either as an
adjunct to chemotherapy or
radiation therapy, or alone. Careful analysis of the evidence seems to
suggest it can be an excellent aid
against debilitation in weight loss, loss of appetite, pain and the subjective
malaise or psychological
depression so often a part of cancer and its treatments. Not only that.
Read for yourself the clinical
evidence and you will find that in some instances HYDRAZINE SULFATE reportedly,
has inhibited tumor
Potential side effects include:
mild sensations of itching of the skin.
As with an adverse reaction to any substance, your judgement must be
relied upon to discontinue use and consult with your physician immediately.
This should not be tried without the approval and supervision of your
physician to begin with.
Possible beneficial effects include:
a reduction of pain, suffering and the wasting-away
a stabilization of symptoms and tumor growth
an improvement in appetite and weight gain
an enhancement in attitude and strength, and,
in some cases, a disappearance of symptoms and remission of the cancer.
In the proper dosages, treatment with HYDRAZINE SULFATE has accompanied
HYDRAZINE SULPHATE IN CANCER TREATMENT
(From the National Cancer Institute)
CANCER FACTS:National Cancer Institute / National Institute of
- It is estimated that half of all cancer patients experience
cachexia, the rapid loss of a large amount of weight along with fatigue,
weakness, and loss of appetite. Cachexia is a serious problem among
many patients who have advanced cancer. Researchers are looking for
ways to provide supportive care to cancer patients with cachexia.
- Scientists are studying the biological reasons for
cachexia. They have found that many patients with cachexia metabolize
food in abnormal ways. One problem is the abnormal metabolism of sugars
and starch, which are a major source of energy from food. Normally,
the body converts these carbohydrates to glucose, the simple sugar that
can then be used by cells for energy. However, if glucose is not metabolized
properly, the body will break down fat and other tissue, such as muscle,
for energy. As a result, abnormal carbohydrate metabolism can lead to
weight loss and weakness.
- Hydrazine sulfate is a chemical that interrupts abnormal
glucose metabolism. Some studies have suggested that use of this drug
helps improve patients' appetite and increase their weight. A study
of hydrazine sulfate was conducted at Harbor-UCLA Medical Center in
Torrance, California. This small study involved 65 cancer patients and
showed improved survival in those patients who were in good condition.
- Based on these findings, the National Cancer Institute
sponsored three randomized studies involving a total of more than 600
patients who had nonsmall cell lung cancer or advanced colorectal cancer.
The patients were randomized to receive either hydrazine sulfate or
a placebo. Researchers compared the treatment and placebo groups to
determine whether hydrazine sulfate was effective in improving survival,
reducing weight loss, and improving quality of life. None of the studies
showed any significant benefit (in terms of survival, weight loss, or
quality of life) to treatment with hydrazine sulfate.
- At this time, hydrazine sulfate is not approved for
use in supportive care for cancer patients in the United States. It
cannot be routinely prescribed by physicians.
- Supportive care for patients coping with the side
effects of cancer and its treatment is an important part of good medical
care. Researchers continue to look for ways to control weight loss in
cancer patients. Drugs under study at this time include megestrol acetate,
fluoxymesterone, and dexamethasone.
- Results of the three studies of hydrazine sulfate
supported by the National Cancer Institute are published in the Journal
of Clinical Oncology, Vol. 12, June 1994, pp. 1113-1129. The articles
"Cisplatin, Vinblastine, and Hydrazine Sulfate in Advanced, Non-Small-Cell
Lung Cancer: A Randomized Placebo-Controlled, Double-Blind Phase III Study
of the Cancer and Leukemia Group B" by Michael P. Kosty et al.
"Randomized Placebo-Controlled Evaluation of Hydrazine Sulfate in
Patients With Advanced Colorectal Cancer" by Charles L. Loprinzi
"Placebo-Controlled Trial of Hydrazine Sulfate in Patients With
Newly Diagnosed Non-Small-Cell Lung Cancer" by Charles L. Loprinzi
The Cancer Information Service (CIS), a program of the National Cancer
Institute, is a nationwide telephone service for cancer patients and their
families, the public, and health care professionals. CIS information specialists
have extensive training inproviding up-to-date and understandable information
about cancer. They can answer questions in English and Spanish and can
send free printed material. In addition, CIS offices serve specific geographic
areas and have information about cancer-related services and resources
in their region.
THE REAL STORY
Hydrazine Sulfate, a simple, off-the-shelf chemical, dramatically reverses
cachexia (ka-KEK-si-a), the wasting-away process that kills two thirds
of all cancer patients. This inexpensive drug, with little or no side
effects, also has a clinically documented antitumor action. It causes
malignant tumors to stop growing, to reduce in size, and, in some cases,
to disappear. A growing number of cancer patients diagnosed as terminal
have experienced tumor stabilization and remission through hydrazine sulfate
therapy. About half of all patients who take hydrazine sulfate experience
weight gain, restored appetite, extended survival time, and a significant
reduction in pain and suffering. Many patients report an increase in vigor
and strength and the disappearance of symptoms of the disease, along with
feelings of well-being and optimism. While hydrazine sulfate may not be
a sure-fire cancer cure, large-scale clinical trials suggest that it effects
every type of tumor at every stage. It can be administered either alone
or in combination with cytotoxic chemotherapy or radiation to make the
cancer more vulnerable to these standard forms of treatment.
Hydrazine Sulfate is now undergoing Phase III trials sponsored by the
National Cancer Institute. It is available to patients as a "compassionate
IND (Investigational New Drug)," a designation conferred by the Food
and Drug Administration on a case by case basis, so it is no longer, strictly
speaking, an "unconventional therapy." Yet even though hundreds
of patients across the country are using the drug, it is not widely discussed
or disseminated among practicing physicians and its promise remains largely
untapped twenty-four years after it was first proposed as an anticancer
treatment by Dr. Joseph Gold. Meanwhile, hydrazine sulfate is widely available
in the Commonwealth of Independent States (formerly the Soviet Union),
where researchers have followed up on Gold' s pioneering work with over
ten years ofinvestigation supporting the drug's effectiveness.
"We've gone from a red lift to a yellow light, and hopefully will
go to a green light," says Dr. Gold, director of the Syracuse Cancer
Research Institute in Syracuse, New York, which he founded in 1966. Since
his discovery in 1968 that hydrazine sulfate can prevent the wasting-away
process in cancer patients and inhibit tumor growth, Gold has waged courageous
uphill battle to win acceptance for his nontoxic chemotherapy by the medical
The American Cancer Society put hydrazine sulfate on its Unproven Methods
blacklist in 1976. It condemned and stigmatized the drug following a clinical
trial on twenty-nine patients at Memorial Sloan-Kettering Cancer Center
in New York. But it is now widely acknowledged that the Sloan Kettering
tests were botched.
When Dr. Gold made an unannounced visit to the hospital in 1974, he discovered,
to his horror, that "many patients in the study were either being
underdosed or overdosed. Some people who were beginning to show anticachexia
response were suddenly being given 90 to 100 milligrams at one time. All
this was in clear violation of the drug protocols and of our joint agreements,"
said Gold. The study's protocol called for patients to receive 60 milligrams
once a day for the first three days, twice a day for the next three days,
and three times a day for the following six weeks. Therefore, some patients
were getting a 67 percent overdose.
In a letter of protest to Sloan Kettering, Gold pointed out that some
patients were receiving a massive, single dose of approximately 120 to
190 milligrams a day (instead of the usual two or three 60 milligram doses),
"which quickly wiped out whatever good response they were beginning
to show." The study was so poorly executed that it could never be
published today, he maintains.
Nevertheless, the damage was done. The ACS's blacklisting of hydrazine
sulfate caused Gold's funding to dry up and scared away other researchers
from following up on his early papers.
But Gold refused to give up. In 1975, he did a study of the drug's effects
on eighty-four advanced cancer patients. A total of 70 percent of them
experienced weight gain (or the cessation of weight loss) and reduced
pain. Only 17 percent showed tumor improvements. Meanwhile, Russian scientists
at Leningrad's Petrov Research Institute were getting impressive results.
In one study of forty-eight terminal cancer patients treated with hydrazine
sulfate, 35 percent had tumor stabilization or regression and 59 percent
showed "subjective response" (ability to function normally,
complete disappearance or marked reduction of pain, and so forth).
As a result of these and other favorable studies, the American Cancer
Society announced in 1979 that it was removing hydrazine sulfate from
its official blacklist. Only four other "unproven methods" that
were once stigmatized on the ACS list as "quackery" have been
removed from it. However, the ACS included hydrazine sulfate in the 1979
edition of the Unproven Methods list, and that edition continued to be
circulated until 1982. Hydrazine sulfate was finally removed from the
list the next time the list was revised, in July 1982.
Tim Hansen, now in his early twenties, of Minneapolis,
Kansas, is one person grateful for the existence of hydrazine sulfate
therapy. In August 1984, when he was eleven years old, Tim was diagnosed
with three inoperable malignant tumors that were growing quickly in
his brain. He was placed on radiation therapy, but his health steadily
deteriorated until, by early 1985, his weight had dropped to fifty-five
pounds. "The radiation harmed his mental functioning, and in January
1985 the surgeon told me that Tim had one week to live," says Gloria
Hansen, Tim's mother.
In February, after reading a short item about hydrazine
sulfate in Mc Call's, Gloria and her husband, Ray, got in touch with
Dr. Gold, and Tim was put on hydrazine sulfate therapy by his physicians
in Kansas. By August, his weight was up to seventy-five pounds. By early
1987, two of Tim's tumors had completely vanished. In January 1991,
a computerized axial tomograph (CAT scan) revealed further shrinkage
of the remaining tumor, located in the base of the brain. Dr. Gold plans
to keep Tim on the hydrazine sulfate protocol until the tumor is completely
Tim graduated from high school in 1990 and is now studying
electronics at a trade school, getting A's and B's.
Dr. Gold first stumbled upon hydrazine sulfate's anticancer properties
during his methodical quest for a specific type of therapy. Cancer has
two principal devastating effects on the body. One is the invasion of
the tumor into the vital organs, with the destruction of the organs' functions&emdash;the
most common cause of cancer death in the public's mind. In reality, however,
this accounts for only about 23 percent of the country's half-million
annual cancer deaths.
The other devastating effect of cancer is cachexia, the terrible wasting
away of the body, with its attendant weight loss and debilitation. In
cancer, as in AIDS, patients succumb to the accompanying illnesses, which
they would otherwise survive if not for the wasting syndrome.
"In a sense, nobody ever dies of cancer," notes Dr. Harold
Dvorak, chief of pathology at Beth Israel Hospital in Boston. "They
die of something else - pneumonia, failure of one or another organs. Cachexia
accelerates that process of infection and the building-up of metabolic
poisons. It causes death a lot faster than the tumor would, were it not
for the cachexia."
Halting the wasting syndrome instead of directly attacking the cancer
cells with poison was Dr. Gold's plan of attack. As he explains, "Each
of these processes [the tumor invasion of vital organs and cachexia] has
its own metabolic machinery, each is amenable to its own therapy, and
each is to some degree functionally interdependent on the other. In the
interest of treating the totality of malignant disease, each of these
processes warrants intervention. Such an approach, dealing with both major
underpinnings of the cancerous process - mitogenic and metabolic - affords
the greatest promise for eliciting long-term, symptom-free survival and
the potential for disease eradication."
WHAT CAUSES CACHEXIA?
Cancer cells gobble up sugar ten to fifteen times more than normal cells
do. The sugar consumed by the cancer cells is generated mainly from the
liver, which converts lactic acid into glucose. (Normal cells are far
more efficient users of glucose, which they derive from the food we eat,
not from lactic acid.) When cancer cells use sugar (glucose) as fuel,
they only partially metabolize it. Lactic acid&emdash;the waste product
of this incomplete combustion&emdash; spills into the blood and is
taken up by the liver. The liver then recycles the lactic acid (and other
breakdown products) back into glucose, and the sugar is consumed in ever-increasing
amounts by voracious cancer cells. The result is a vicious cycle, what
Dr. Gold calls a "sick relationship" between the liver and the
cancer. The patient's healthy cells starve while the cancer cells grow
vigorously. Some healthy cells even dissolve to feed the growing tumor.
To break this sick relationship, Gold reasoned, all he needed was to
find a safe, nontoxic drug that inhibits gluconeogenesis ( the liver's
recycling of lactic acid back into glucose). In 1968, he outlined his
theory in an article published in Oncology. "The silence was deafening,
he recalls. A year later, by a remarkable coincidence, Gold heard biochemist
Paul Ray deliver a paper explaining that hydrazine sulfate could shut
down the enzyme necessary for the production of glucose from lactic acid.
Gold had chanced upon an eminently logical way of starving cancer. He
immediately tested hydrazine sulfate on mice and found that in accord
with his theory, the drug inhibited both gluconeogenesis and tumor growth.
Over the years, many dramatic remissions in patients on hydrazine sulfate
therapy have been reported.
In one case, a sixty-two-year-old woman with widely
disseminated cancer of the cervix, in a very debilitated condition,
was put on the drug. After one week, a secondary tumor the size of an
orange had completely disappeared, much to the amazement of the woman's
doctors, and neck nodes had become markedly smaller. After three weeks
on the therapy, the patient had gained weight and was active and in
good spirits. The woman was discharged from the hospital a short time
In 1987, Erna Kamen, a sixty-three-year-old lung cancer
patient, was administered hydrazine sulfate after her discharge from
a Sarasota, Florida, hospital. "Basically, my mother was sent home
to die," says Jeff Kamen, an Emmy-winning television reporter.
"She'd lost a significant amount of weight by then, and she had
no appetite and virtually no will to do anything." A doctor had
told Jeff's father, Ira Kamen, that hydrazine sulfate offered at least
"a shot in the dark." So one Monday in August 1987, a home
nurse gave Mrs. Kamen one hydrazine sulfate pill shortly before serving
lunch. "On Tuesday morning," recalls Jeff, "there was
a commotion in the house. My mother had risen from her bed like the
phoenix rising from the ashes. She was demanding that the nurse bring
her downstairs so that she could have breakfast with me.... When people
you love get into this kind of facedown with death, you're just incredibly
grateful for each moment."
As Jeff describes his mother's recovery, "her
searing pain was gone; her appetite returned at a gallop." Within
three weeks, her racking cough had vanished and she could walk unaided.
"In the months before her death, she went on television with me
to tell the nation about hydrazine sulfate. The National Cancer Institute
stopped trashing hydrazine sulfate and began referring inquiries to
the UCLA Medical School team whose work had validated the effectiveness
of the drug long before Erna Kamen began taking it." Jeff attributes
his mother's death months later to her being "mistakenly taken
off hydrazine sulfate and subjected to an unproven experimental substance."
With cancer patients, hydrazine sulfate is usually administered orally
in 60-milligram capsules or tablets, approximately one to two hours before
meals. It is given at first once a day for several days, then twice a
day, then three or four times daily, depending on the patient's response
and the physician's judgment. On such a regimen, many terminal and semiterminal
patients have derived considerable benefit, although patients in the early
stages of the disease derive the most benefit from the treatment.
Approximately half of the patients to whom the drug is properly administered
in the early stages of the disease show an almost immediate weight gain
and reversal of symptoms; in some instances, the tumor eventually disappears.
The common types of cancer most frequently reported to benefit from hydrazine
sulfate therapy are:
lung (bronchogenic) cancer
Hodgkin's disease and other lymphomas
and breast cancer
.Some less common types of cancer also benefit.
"Whether hydrazine sulfate should be used in conjunction with other
agents seems to be dependent on whether these agents are doing the patient
any demonstrable good," according to Dr. Gold. "In the instances
in which these agents have been doing good, hydrazine sulfate should be
used in conjunction with them. However - and especially with those cases
on toxic drugs - in instances in which the drugs have been doing no evident
good, it is probably best to withdraw such drugs and use hydrazine sulfate
alone." Many alternative therapists disagree. They see hydrazine
sulfate as mainly an adjunctive treatment, albeit a potentially powerful
Critics have made much of the fact that hydrazine sulfate, a common industrial
chemical, is found in such products as rocket fuel, insecticides, and
rust-prevention agents. For medical purposes, however, the salt is refined,
purified, and used in reagent-equivalent grades. Given to patients in
minuscule amounts, it occasionally produces mild, transient side effects
such as nausea, dizziness, itching of the skin, drowsiness, and euphoria,
but such side effects are minimal, especially when compared with the devastating
effects of standard chemotherapy.
A very small percentage of patients undergoing long-term, high dosage
hydrazine sulfate therapy experience pain or temporary numbness in their
extremities, but this condition is quickly controlled by reducing the
dosage and administering vitamin B6. In no known cases has hydrazine sulfate
depressed or destroyed white blood cells or bone marrow, as conventional
chemotherapy often does. In general, toxicity has been exceedingly low
The most recent study of this drug, however, concluded that hydrazine
sulfate appears not to be beneficial and may even have neurological side
effects. This study involved a nationwide, twenty-month trial with 291
advanced non-small-cell lung cancer patients, all of whom received chemotherapy.
In the double-blind phase, half were given hydrazine sulfate, while the
other half received a placebo. Patients receiving hydrazine sulfate had
a median survival of 7.62 months, while the comparable figure for those
on placebo was 7.5 months. Hydrazine sulfate had no effect on cancer cachexia,
according to Michael Kosty, M.D., an oncologist with Scripps Clinic and
Research Foundation in La Jolla, California, who was the study's principal
investigator, nor were differences noted between the two groups in anorexia
or weight gain. Furthermore, the placebo group rated their quality of
life higher than did those patients taking hydrazine sulfate, and some
hydrazine sulfate patients experienced loss of sensation and motor function.
"Therefore, the best we can say about this drug is that it has no
effect and may even be deleterious," Dr. Kosty was quoted as saying
in a summer 1992 issue of ASCO Highlights, a publication of the American
Society of Clinical Oncology.
Dr. Rowan Chlebowski, director of a UCLA research project on hydrazine
sulfate, conservatively estimates that the drug could benefit about half
a million cancer patients each year in the United States alone. His team
has conducted many clinical studies of hydrazine over two decades. Dr.
Chlebowski says that the drug's indirect mode of action against tumors
is problematic to more cautious investigators. "We found that hydrazine
sulfate was an anticachexia agent that indirectly induced antitumor responses
without much toxicity. Its action is not directed at cancer cells yet
it may profoundly affect them."
Dr. Chlebowski and his colleagues at the Harbor-UCLA Medical Center in
Torrance, California, recently found evidence that hydrazine sulfate added
to conventional chemotherapy improves the nutritional status and prolongs
the life of patients with non-small-cell lung cancer, especially deadly
forms of the disease. In the January 1990 issue of the prestigious Journal
of Clinical Oncology, he reports that earlier-stage patients have a median
survival time of at least 328 days, compared to 209 days for the placebo
group. There is no curative therapy for this type of lung cancer, so the
results, if confirmed, seem promising.
The wasting syndrome seen in cancer patients is also a prime risk factor
for AIDS patients with Kaposi's sarcoma. There is evidence that hydrazine
sulfates capacity to stop cachexia may save many AIDS patients. Currently,
Dr. Chlebowski is planning a study to test hydrazine sulfate as an anticachexia
agent in patients who are infected with HIV and have lost weight.
Even though hydrazine sulfate is now undergoing extensive Phase 111 trials
sponsored by the National Cancer Institute, resistance to this inexpensive,
nontoxic chemotherapy in orthodox medical circles persists. Dr. Vincent
DeVita, former director of the NCI, told a Washington Post reporter in
1988 that he thought hydrazine was a "ho-hum idea." Dr. Gold,
until recently, has been frozen out of the "war on cancer."
Two articles on cachexia published in July 1990 in the prestigious Cancer
Research journal fail to reference any of Gold's path-breaking work, and
one even denies there is any effective treatment for the wasting-away
Dr. Gold, who does not treat patients, says that the cost of hydrazine,
at most, should be nominal - comparable to the daily cost of insulin and
other supplies for diabetics. "Until a pharmaceutical company sponsors
the drug through the FDA, it will not be widely in use," he predicts,
adding, "However, with the new studies, drug companies have suddenly
begun to take notice of this most exemplary drug."
HYDRAZINE SULPHATE AND METABOLIC INHIBITORS The metabolic inhibitor Hydrazine
Sulfate might theoretically induce anabolism by blocking catabolic pathways,
presumably by inhibiting the gluconeogenic enzyme phosphoenolpyrovate
carboxykinase and preventing the energy requiring conversion of lactate
Early studies had reported no significant benefit stemming from Hydrazine
Sulfate use in cancer patients. However, more recent studies have found
that Hydrazine Sulfate therapy improved appetite and increased serum albumin
and caloric intake in lung cancer patients. Ongoing clinical trials have
been designed to further evaluate these encouraging new clinical findings
in cancer patients. Whether Hydrazine Sulfate will produce a similar effect
in AIDS patients is not yet known.
MAO INHIBITOR WARNING:
If you are taking a MAO Inhibitor (one of a class of drugs prescribed
to counter depression, lower blood pressure, and treat infections and
cancer), avoid the chemical tyramine and its precursor, tyrosine. Combining
MAO inhibitors with tyramine causes the blood pressure to soar. Patients
taking Hydrazine Sulfate who experience the symptoms indicating high blood
pressure, should discontinue medication and contact their physician.
Tyramine-containing foods include: almonds, avocados, bananas, beef or
chicken liver, beer, cheese (including cottage cheese), chocolate, coffee,
fava beans, herring, meat tenderizer, peanuts, pickles, pineapple, pumpkin
seeds, raisins, sausages, sesame seeds, sour cream, soy sauce, wine, yeast
extracts (including brewers yeast), yogurt, and other foods. In general,
avoid any high-protein food that has undergone ageing. Over-the-counter
mouthwash, cold and allergy remedies should also be avoided if it has
any alcohol content. Hydrazine Sulfate is a MAO Inhibitor.
IMPORTANT: MAO Inhibitors - The special diet restrictions apply only
to patients with High Blood Pressure. Others may eat all these foods in
As observed in the Syracuse Cancer Research Institute,
the suggested clinical dose for cancer patients is as follows: Persons
95 lbs. or less (30mg capsule):
Day 1: One (1) capsule with breakfast for three (3) days
Day 4: Increase dosage to one (1) capsule with breakfast, and one (1)
capsule/tablet with lunch, for
three (3) days.
Day 7: Increase dosage to one (1) capsule with breakfast, one (1) capsule/tablet
with lunch, and one
(1) capsule/tablet with dinner. This is a maintenance dose.
Persons between 95 and 121 lbs. (60mg capsule):
Day 1: One (1) capsule with breakfast for three (3) days
Day 4: Increase dosage to one (1) capsule with breakfast, and one (1)
capsule with lunch. This is a
Persons over 121 lbs. (60mg capsule):
Day 1: One (1) capsule with breakfast for three (3) days
Day 4: Increase dosage to one (1) capsule with breakfast, and one (1)
capsule with lunch, for three
Day 7: Increase dosage to one (1) capsule with breakfast, one (1) capsule
with lunch, and one (1)
capsule with dinner.
Maintain this dose for six (6) weeks, followed by a two (2) week rest
period. After two (2) weeks rest period, dosage may
be repeated as from day 1.
Taking a single dose of more than 60 mg. is not recommended
in the clinical studies. As with any drug, overdosing in any way is greatly
discouraged and potentially dangerous.
HYDRAZINE SULFATE is being tested with promising results at cancer institutes
and research centers around the world. It is also being used by some HIV
and AIDS patients to combat the characteristic wasting away of the body.
HYDRAZINE SULFATE's original proponent, Dr. Joseph Gold of the Syracuse
Cancer Research Institute of New York has been fighting years for acceptance
of this virtually side effect free, non toxic cancer therapy despite the
reluctance of more rigid, conventionally entrenched, orthodox practitioners
who now may be taking another look at the results in both America and
The use of tranquilizers, barbiturates and/or alcoholic beverages with
hydrazine sulfate destroys the efficacy of this drug and increases patient
morbidity. Pregnant and nursing mothers should consult their physician
before taking any substance, including HYDRAZINE SULFATE.
HYDRAZINE SULFATE (60mg - 100 caps) $60(US) $75(CDN)
To find out more, Call Darrell L. Wolfe at
The Wolfe Clinic TOLL FREE 1-800-592-9653
If our 1-800 number is not available from your area,
please call us at
Updated April 29, 2002
The statements enclosed herein have not been evaluated
by the Food and Drug Administration. The products mentioned on this site
are not intended to diagnose, treat, cure, or prevent any disease. Information
and statements made are for education purposes and are not intended to
replace the advice of your family doctor.
The Wolfe Clinic does not dispense medical advice, prescribe,
or diagnose illness. We design individual nutritional programs that allow
the body to rebuild and heal itself.
top of page